Wall Street analyst estimates for Alnylam Pharmaceuticals, Inc. (ALNY): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders.
Consensus price target
$330.54 (+100 % vs price $165.00)
between $225.00 and $455.00 · 17 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $5.4B | $5.3B – $5.7B | $17.81 | 14 |
| 2027E | $6.7B | $5.9B – $7.7B | $9.19 | 15 |
| 2028E | $7.9B | $6.2B – $9.8B | $11.47 | 16 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 38 |
| Hold | 13 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 52 |
| Avg rating (−2 sell to +2 buy) | 0.71 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-11 | $1.75 | ||
| 2026-10-29 | $16.26 | $1.66 | +879.5% |
| 2026-07-30 | $1.21 | $1.63 | -25.8% |
| 2026-04-30 | $1.51 | $0.87 | +73.2% |
| 2026-02-12 | $0.82 | $1.16 | -29.3% |
| 2025-10-30 | $1.84 | $0.56 | +228.0% |
| 2025-07-31 | $-0.51 | $-0.54 | +6.2% |
| 2025-05-01 | $-0.44 | $-0.89 | +50.6% |
Valuation Ratios
| P/E Ratio | 8.33 |
| Price / Book | 6.13 |
| EV / EBITDA | 17.31 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $47.2M | $89.9M | $74.9M | $219.8M | $492.9M | $844.3M | $1.04B | $1.83B | $2.25B | $3.71B |
| Cost of Revenue | 0 | $13.4M | $1.8M | $25.1M | $78.1M | $140.1M | $168.8M | $310.4M | $323.4M | $677.2M |
| Gross Profit | $47.2M | $76.5M | $73.1M | $194.7M | $414.8M | $704.1M | $868.6M | $1.52B | $1.92B | $3.04B |
| Research & Development | $382.4M | $390.6M | $505.4M | $655.1M | $654.8M | $792.2M | $883.0M | $1.00B | $1.13B | $1.32B |
| Selling, General & Admin | $89.4M | $199.4M | $382.4M | $479.0M | $588.4M | $620.6M | $770.7M | $795.6M | $975.5M | $1.21B |
| Operating Expenses | $471.7M | $590.0M | $887.8M | $1.13B | $1.24B | $1.41B | $1.65B | $1.80B | $2.10B | $2.54B |
| Operating Income | -$424.6M | -$500.1M | -$814.7M | -$939.4M | -$828.4M | -$708.7M | -$785.1M | -$282.2M | -$176.9M | $501.6M |
| EBITDA | -$409.5M | -$488.2M | -$754.2M | -$830.9M | -$696.7M | -$661.6M | -$926.6M | -$258.2M | -$178.8M | $631.4M |
| Interest Expense | 0 | 0 | 0 | 0 | $84.5M | $143.0M | $156.0M | $121.2M | $141.9M | $252.6M |
| Pre-tax Income | -$410.1M | -$490.9M | -$760.7M | -$885.3M | -$855.6M | -$852.1M | -$1.13B | -$433.5M | -$377.4M | $323.2M |
| Income Tax | 0 | 0 | $823,000 | $863,000 | $2.7M | $680,000 | $4.2M | $6.7M | -$99.2M | $9.4M |
| Net Income | -$410.1M | -$490.9M | -$761.5M | -$886.1M | -$858.3M | -$852.8M | -$1.13B | -$440.2M | -$278.2M | $313.7M |
| EPS | $-4.79 | $-5.42 | $-7.57 | $-8.11 | $-7.46 | $-7.20 | $-9.30 | $-3.52 | $-2.18 | $2.39 |
| EPS (Diluted) | $-4.79 | $-5.42 | $-7.57 | $-8.11 | $-7.46 | $-7.20 | $-9.30 | $-3.52 | $-2.18 | $2.33 |
| Shares Outstanding (Diluted) | 85.6 M | 90.6 M | 100.6 M | 109.3 M | 115.0 M | 118.5 M | 121.7 M | 124.9 M | 127.7 M | 134.7 M |
Price
| Price | $165.00 (closing price, October 30, 2026) |
| Market Cap | $22.1B |
| Exchange | NASDAQ |
| Country | US |
Related companies: IONS · ARWR · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of ALNY: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks